Floatz logo

Olaparib

Refractory Hodgkin Lymphoma

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Refractory Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Vesanoid
Rita Assi
Phase 2B
5-azacytidine
M.D. Anderson Cancer Center
Phase 2B
DEZAPELISIB
Incyte Corporation
Phase 2CCC
hcb301
FBD Biologics Limited
Phase 1CC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →